Related Experiment Video
Updated: Aug 9, 2026
Reusable Single Cell for Iterative Epigenomic Analyses
Published on: February 11, 2022
Epigenomics AG
Christoph Sachsenmaier1, Achim Plum1
1Epigenomics AG, Kleine Präsidentenstr. 1, 10178 Berlin, Germany. christoph.sachsenmaier@epigenomics.com www.epigenomics.com.
Abstract:
Earlier diagnosis and a more individualized choice of treatment options has the potential to greatly improve the outcome of life-threatening diseases. DNA methylation has proven to be a rich source of biomarkers for diagnosis, prognosis and drug response prediction in cancer and other diseases. Epigenomics AG makes use of DNA methylation biomarkers to develop in vitro diagnostic test products. The product pipeline comprises screening tests for the early detection of cancer in body fluids and molecular pathology tests on routinely available tissue samples for cancer prognosis. In collaborations with pharmaceutical and biotechnology companies, Epigenomics provides access to its broad range of technologies for the support of drug development and commercialization by patient stratification and drug response prediction.
Related Concept Videos
00:46Genomic DNA in Prokaryotes
Genomic Diversity in Bacteria
Although bacterial genomes are much...
02:35DNA Agarose Gel Electrophoresis
Gel extraction follows five major steps: running gel electrophoresis to separate fragments, isolating the individual bands, extracting DNA from those bands, and removing the dye and salts from the extracted mixture to obtain pure DNA.
In cloning experiments, both the insert and vector DNA...